IND for Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Approved by NMPA
December 24, 2025
Source: drugdu
29
On the morning of December 24, Abbisko Therapeutics announced on the Hong Kong Stock Exchange that its subsidiary, Shanghai Abbisko Biotechnology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China for the Investigational New Drug (IND) application of its oral, highly potent, and selective small-molecule KRAS G12D inhibitor ABSK141. The drug is intended for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.
Reference：https://finance.eastmoney.com/a/202512243600135972.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Over $2 billion! Another major deal for a domestically developed innovative drug December 24, 2025
- Good news for middle-aged and elderly men! Taincon has become the first generic version of a compound drug for benign prostatic hyperplasia December 24, 2025
- BeiGene – Catadegbrutinib Initiates International Multicenter Phase II Clinical Trial for B-Cell Leukemia December 24, 2025
- Wantai Bio’s bivalent HPV vaccine (Escherichia coli) was shortlisted for the National Immunization Program (NIP) December 24, 2025
- Subsidiary Receives Clinical Trial Approval for Daratumumab Injection December 24, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
